|Intramuscular injection (IM), intravenous (IV)|
|Defined daily dose||Not established|
|Chemical and physical data|
|Molar mass||31732.06 g·mol−1|
|(what is this?)|
Pegaspargase, sold under the trade name Oncaspar, is a medication used in the treatment of acute lymphoblastic leukemia (ALL). Often it is used together with anthracycline, vincristine, and prednisone. It is used by injection.
Common side effects include allergic reactions, blood clotting problems, high blood sugar, liver problems, pancreas inflammation, and blood clots in the brain. Its use during pregnancy may harm the baby. It is a modified version of the enzyme asparaginase which has undergone PEGylation. It works by breaking down asparagine, decreasing its availability to make protein.
Pegaspargase was approved for medical use in the United States in 1994. It is on the World Health Organization's List of Essential Medicines. It is made by Sigma-Tau. In the United States it costs about $US17,800 per 3,750 units vial.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 9 September 2020. CS1 maint: discouraged parameter (link)
- Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708.
- "Pegaspargase Monograph for Professionals". Drugs.com. Retrieved 11 October 2019. CS1 maint: discouraged parameter (link)
- "Pegaspargase (Oncaspar) Use During Pregnancy". Drugs.com. Retrieved 11 October 2019. CS1 maint: discouraged parameter (link)
- "UNM Cancer Center". Archived from the original on 3 September 2006. Retrieved 28 August 2007. CS1 maint: discouraged parameter (link)
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Oncaspar Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 11 October 2019. CS1 maint: discouraged parameter (link)